Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.61 USD
Change Today +0.05 / 0.28%
Volume 84.2K
ANGO On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

angiodynamics inc (ANGO) Snapshot

Open
$17.50
Previous Close
$17.56
Day High
$17.77
Day Low
$17.43
52 Week High
01/29/15 - $19.80
52 Week Low
04/15/14 - $13.06
Market Cap
630.8M
Average Volume 10 Days
123.9K
EPS TTM
$0.32
Shares Outstanding
35.8M
EX-Date
--
P/E TM
55.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANGIODYNAMICS INC (ANGO)

angiodynamics inc (ANGO) Related Businessweek News

No Related Businessweek News Found

angiodynamics inc (ANGO) Details

AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The company offers manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, including laser system products used in endovascular laser procedures to treat superficial venous diseases, as well as sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities. It also provides angiographic catheters and guidewires used during peripheral vascular interventional procedures; venous drainage cannula intended for use as a venous drainage cannula during extracorporeal bypass and cardiopulmonary bypass circuit intended for use in procedures requiring extracorporeal circulatory support; and drainage products that drain abscesses and other fluid pockets. In addition, the company offers thrombolytic catheters that are used to deliver thrombolytic agents; micro access sets for minimally-invasive procedures; dialysis catheters that provide short and long-term vascular access for dialysis patients; and peripherally inserted central catheters, implantable ports, and central venous catheters. Further, it provides radiofrequency ablation products, soft tissue surgical ablation products, and microwave ablation products. The company markets and sells its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly and through distributors in the United States and internationally. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

1,300 Employees
Last Reported Date: 01/8/15
Founded in 1988

angiodynamics inc (ANGO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $873.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $367.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $308.3K
Senior Vice President of Global Franchise, On...
Total Annual Compensation: $276.8K
Senior Vice President of Administration
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2014.

angiodynamics inc (ANGO) Key Developments

AngioDynamics Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 02:05 PM

AngioDynamics Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Joseph M. Devivo, Chief Executive Officer, President and Director.

AngioDynamics Receives Expanded No Chest X-Ray FDA Clearance for Celerity Tip Location System

AngioDynamics announced the U.S. Food and Drug Administration cleared an expanded indication for the Celerity tip location system. The new clearance allows for the elimination of a follow-up X-ray when the Celerity system is used to aid in positioning Peripherally Inserted Central Catheters in adults. The system works by utilizing the patient's cardiac electrical activity to provide real time catheter tip location, offering accuracy on par with similar devices currently marketed, at or above 97% as compared to chest X-ray.

AngioDynamics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended November 30, 2014; Provides Earnings Guidance for the Third Quarter of 2015; Revenue Earnings Guidance for the Fiscal Year 2015

AngioDynamics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended November 30, 2014. Net sales of $92.1 million increased 4% compared with last year's second quarter net sales of $88.6 million. Excluding the planned wind-down of the supply agreement with Boston Scientific (BSC), second quarter sales were up 5% to $91 million compared to $86.9 million in last year's second quarter. The following sales comparisons exclude the BSC supply agreement. The company's net income was $1.3 million, or $0.04 on a per share basis, compared to a net loss of $0.3 million, or $0.01 on a per share basis, a year ago. Excluding the items, adjusted net income was $6.2 million, or $0.17 per share, for the second quarter compared to net income of $4.9 million, or $0.14 per share, for the year ago quarter, representing a 21% increase. Second quarter EBITDA grew to $11.9 million, or $0.33 per share, compared to $8.6 million, or $0.24 per share, in the year ago period. Adjusted EBITDA, excluding the items, was $15.9 million, or $0.44 per share, compared to $13.5 million, or $0.38 per share, in the year ago comparable period, representing a 18% increase. Operating income was $4,575,000 against $1,441,000 a year ago. Profit before income taxes was $2,830,000 against loss before income taxes of $350,000 a year ago. Net cash used in operating activates was $2,147,000 against net cash provided by operating activities of $8,458,000 a year ago. Additions to property, plant and equipment was $2,419,000 against $4,288,000 a year ago. Acquisition of intangible assets was $96,000 against $150,000 a year ago. For the six months ended November 30, 2014, net sales were $179.5 million, a 4% increase compared to the $172.2 million reported a year ago. The Company's net income was $1.8 million, or $0.05 per share, compared to net loss of $0.6 million, or $0.02 per share, reported a year ago. Excluding the items, adjusted net income was $11.9 million, or $0.33 per share, compared to net income of $8.9 million, or $0.25 per share, a year ago, representing a 32% increase. EBITDA was $21.8 million, or $0.61 per share, compared to EBITDA of $16.7 million, or $0.47 per share, a year ago. Adjusted EBITDA, excluding the items was $30.4 million, or $0.84 per share, compared to $25.6 million, or $0.73 per share, in the year ago period, representing a 19% increase. Operating income was $7,817,000 against $2,843,000 a year ago. Profit before income taxes was $4,248,000 against loss before income taxes of $913,000 a year ago. Net cash provided by operating activities was $3,205,000 against $15,758,000 a year ago. Additions to property, plant and equipment was $7,523,000 against $7,191,000 a year ago. Acquisition of intangible assets was $250,000 against $150,000 a year ago. For the fiscal year of 2015, as a result of continued strong operational performance, the company is raising both the lower and upper end of adjusted earnings per share (EPS) guidance to a range of $0.66 to $0.72. Net sales guidance range at $362 million to $368 million. For the third quarter, the company is anticipating net sales to range from $88 million to $91 million in the third quarter, 5% at the top end excluding supply agreement. Adjusted EPS excluding amortization is expected to be $0.14 to $0.17, representing a 21% improvement over third quarter fiscal 2014 at the high end.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANGO:US $17.61 USD +0.05

ANGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aerovironment Inc $26.53 USD -0.07
CTS Corp $17.65 USD +0.02
Orthofix International NV $30.46 USD +0.24
Raven Industries Inc $20.45 USD -0.22
Sparton Corp $24.33 USD -0.07
View Industry Companies
 

Industry Analysis

ANGO

Industry Average

Valuation ANGO Industry Range
Price/Earnings 100.0x
Price/Sales 1.8x
Price/Book 1.2x
Price/Cash Flow 29.8x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGIODYNAMICS INC, please visit www.angiodynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.